DOCSLIB.ORG

2020 Korea Innovative PHAR

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text

Load more

2020 This brochure illustrates a project promoted by Korean pharmaceutical companies and with support from the Korean government, to enter global markets. You’ll meet the Korean pharmaceutical industry as a reliable partner for global collaboration. Contents 02 Current Status of Korean Pharmaceutical Market 08 Introduction of Korean Innovative Pharmaceutical Company Certification System 10 Information of Korean Innovative Pharmaceutical Company 55 Supplement Current Status of Korean Pharmaceutical Market Current Status of (Market size) Korean pharmaceutical market passed the $21 billion mark in 2018. Its Korean Pharmaceutical Market growth has been driven by leading Korean companies, which have been releasing new global drugs and achieving technology exports. Pharmaceuticals exports have increased at a CAGR of 17.9% for the past five years (2014-2018), fueled especially by increases in Korean drugs entering into global markets. Current status of Korean pharmaceutical market (unit: million dollar, %) Year-on-year CAGR Category 2014 2015 2016 2017 2018 growth rate (’14~’18) Market size 18,396 16,963 18,712 19,508 21,004 7.70% 3.40% Production 15,593 14,991 16,198 18,000 19,176 6.50% 5.30% Exports 2,416 2,946 3,119 4,069 4,673 14.80% 17.90% Imports 5,219 4,918 5,633 5,577 6,501 16.60% 5.60% Trade balance △2,803 △1,972 △2,514 △1,508 △1,828 △21.2% △10.1% * Source: Press release by the Ministry of Food and Drug Safety (July 29 2019) • ‌The 2018 sales revenue of the listed drug companies (125) is $18,172 million in total (7.5% up from the previous year), with Top 10’s revenue at $7,814 million (8.6%↑). * ‌'18 sales revenue (based on consolidated financial statements) : (Yuhan Corporation) $1,362 million, (Korea Kolmar) $1,181 million, (GC Green Cross) $1,181 million, (Guangdong Pharmaceutical) $1,090 million, (Daewoong Pharmaceutical) $908 mil- lion, (Hanmi Pharm) $908 million - ‌4 domestic companies are among the top 150 pharmaceutical companies in the world based on pre- scription drug sales. * ‌'18 prescription drug sales and global ranking (Evaluate 2019): Daewoong Pharmaceutical (111th, $ 844 million), Hanmi Pharmaceutical (119th, $ 773 million), Yuhan Corporation (122th, $ 762 million), Green Cross (139th, $ 563 million) ‌• ‌The Korean biologics market is valued around $2,026 million (2018), accounting for 10.2% of the entire pharmaceutical market, which is lower than the international level (28.2% in 2018). - ‌Yet it has very high growth potential, with its production and export values rising greatly at a CAGR of 4.3% and 4.6% respectively, for the last five years (2014-2018). - ‌In particular, the biopharmaceutical trade balance has been surplus for four consecutive years following 2015 year due to the increase in exports. - ‌Biosimilars in particular are expected to become a next-generation growth engine as 15 of the 20 drugs approved in Korea were developed by Korean companies. * ‌With the focus on biopharmaceutical pharmaceutical companies such as Samsung Biologics and Celltrion, the world's largest biopharmaceutical production facility is being built and in operation (production capacity of 560,000L, more than 70 companies) Current status of Korean biopharmaceutical market (unit: million dollar, %) Year-on-year CAGR Category 2014 2015 2016 2017 2018 growth rate (‘14~’18) Market size 1,885 1,449 1,577 1,974 2,026 2.6% 2.4% Production 1,597 1,520 1,729 2,300 2,372 3.1% 4.3% Exports 589 809 1,063 1,368 1,559 14.0% 4.6% Imports 877 738 911 1,042 1,213 16.4% 3.3% Trade balance △288 71 152 326 345 5.8% - * Source: Press release by the Ministry of Food and Drug Safety 2 Korean Pharmaceutical Market Current Status of (Current status of businesses) 571 (72%) of 798 pharmaceutical companies in Korea reported production records for 2018, indicating an average production of 45 items per company. Current status of Korean pharmaceutical companies (unit: number, %) CAGR Category 2014 2015 2016 2017 2018 (‘14~’18) Number of manufacturers 851 782 845 806 798 △1.6 Manufacturers with 678 597 599 588 571 △4.2 production records Number of items 29,218 25,890 26,397 26,293 25,939 △2.9 Drug product 18,357 17,907 18,546 19,291 19,239 1.18 Drug substance 10,861 7,983 7,851 7,002 6,700 △11.4 Number of sellers 23,261 24,693 25,862 24,951 26,233 3.1 * Source: Press release by the Ministry of Food and Drug Safety (Current status of R&D) Striving to enhance competitiveness to the level of advanced countries by launching new drugs developed in Korea in overseas markets through the continuous expansion of R&D investments • ‌The total R&D investment by the pharmaceutical companies listed in Korea (125 companies) was $1,423 million in 2018, which accounts for 7.7% of the total sales. - ‌The R&D investment by the top 10 companies was $787 million, which is more than half of the total amount of R&D investment by all the listed pharmaceutical companies, reaching 10.0% of the total sales. - ‌The total R&D expenditure of domestic listed innovative pharmaceutical companies (37 companies) accounted for 74% of total listed companies and the proportion of R&D expenses was 9.3%. R&D investment of major Korean pharmaceutical companies (unit: million dollar, %) Category 2014 2015 2016 2017 2018 Listed companies 932 975 1,152 1,394 1,423 R&D Top 10 companies 510 557 712 798 787 investment Innovative Pharmaceutical Company 744 798 932 1,125 1,059 Listed companies 7.0% 7.1% 7.8% 8.3% 7.7% Ratio to Top 10 companies 10.6% 10.2% 12.1% 11.1% 10.0% sales Innovative 8.6% 8.6% 9.5% 10.7% 9.3% Pharmaceutical Company * Source: Korea Health Industry Development Institute (KHIDI) • ‌Due to the increase in the elderly population and chronic diseases, the biopharmaceutical industry, such as cell therapies and gene therapies, continues to expand due to the growing demand for medicines. - ‌It is expected that the number of licenses will increase after the establishment of the conditional approval system with 15 items of domestic cell therapies approved by Sewon Cellontech's 'Condron' ('01') until '18. * ‌It is a new permit system for cell therapy products for the treatment of life-threatening diseases or severe irreversible diseases (Press release by the Ministry of Food and Drug Safety, July 2016). - Currently, 7 in stem cell therapies of all items have been released worldwide, of which 4 are developed domestically. * (Pharmicell) Hearticellgram-AMI, (Medipost) Cartistem, (Antrogen) Cupistem, (Corestem) Neuronata-R 3 Current Status of (Current status of new drug development) A total of 29 new drugs were developed as of Korean Pharmaceutical Market December 2019 by these efforts of Korean pharmaceutical companies. * 1999-2014: 21 new Korean drugs were developed → 2015-2018: 8 new Korean drugs were developed. New drugs developed since 2015 Company Product Efficacy/Effectiveness Approval Date Crystal Genomics Inc. Acelex Capsule Treatment for osteoarthritis February 5, 2015 DongWha Pharm. Co., Ltd. Zabolante tablet Antimicrobial agent (antibiotics) March 20, 2015 Sivextro tablet Dong-A ST Co., Ltd. Antimicrobial agent (antibiotics) April 17, 2015 Sivextro injection Dong-A ST Co., Ltd. Suganon tablet Antidiabetic drug October 2, 2015 Hanmi Pharmaceutical Co., Ltd. Olita tablet Cancer drug (lung cancer) May 13, 2016 Ildong Pharmaceutical Co., Ltd. Besivo tablet Hepatitis B treatment May 15, 2017 CJ Healthcare K-Cab Tab gastroesophageal reflux disease (GORD) July 5, 2018 (Overseas market entry) Korean companies are creating high value-added through the expansion of their global market shares by launching domestically-developed new drugs in the global market and increasing licensing-out to overseas markets. ‌• ‌15 Korean drugs have obtained approval in the US and EU since 2014, putting sales to developed markets into high gear. - ‌SK Biopharm independently proceeded to the third phase of clinical trials and released it to the United States following new drugs developed in Korea, such as XCOPRI (‘19), which was approved by the FDA. Current status of domestically-developed drugs in terms of approval at home and abroad Reference Drug Approved in Approved Overseas Company Trade Name Efficacy/Effectiveness (Manufacturer) Korea EMA FDA Dong-A ST Co., Ltd. Sivextro* New drug Oxazolidinone antibiotic Apr 2015 Mar 2015 Jun 2014 Merrem Daewoong Meropenem** (AstraZeneca) Carbapenem antibiotic Apr 2010 - Dec 2015 Pharmaceutical Co. Ltd. Botulinum toxin Nov 2013 - Jan 2019 Nabota** (Allergan) Glabellar wrinkles Remicade Rheumatoid arthritis (RA), Remsima* (Johnson & Johnson) ulcerative colitis, etc. Jul 2012 Aug 2013 Apr 2016 RA, chronic lymphocytic Truxima* Rituxan leukemia, non-Hodgkin’s Nov 2016 Feb 2017 (Roche) lymphoma, etc. Celltrion Inc. Herceptin Jan 2014 Feb 2018 Dec 2018 Herzuma* (Roche) Breast cancer Zyvox Tuberculosis, - - Apr 2019 Linezolid** (Pfizer) Wide range of antibiotics Zeffix (GSK), - - Nov 2018 TEMIXYS Viread (Gilead) AIDS 4 Korean Pharmaceutical Market Current Status of Reference Drug Approved in Approved Overseas Company Trade Name Efficacy/Effectiveness (Manufacturer) Korea EMA FDA Benepali (EU)* Eticobo (US)* Enbrel RA, psoriasis, etc. Sep 2015 Jan 2016 Apr 2019 Etoloce (Korea)* (Amgen) Flixabi (EU)* Renflexis (US)* Remicade Remaroche (Johnson & Johnson) RA, ulcerative colitis, etc. May 2016 May 2016 Apr 2017 Samsung Bioepis (Korea)* Co., Ltd. Imraldi (EU)* Hadlima (US)* Humira RA, Crohn's disease, Adalloce (AbbVie) inflammatory bowel Sep 2017 Aug 2017 July 2019 (Korea)* diseases, etc. Ontruzant(EU)* Samfenet Herceptin Breast cancer Nov 2017 Nov 2017 Jan 2019 (Korea)* (Roche) SK Chemicals AFSTYLA New biologic Antihemophilic drug - Jan 2017 May 2016 SK Biopharm Sunosi New drug Sleep disorder - - March 2019 aceuticals XCOPRI® New drug Epilepsy - - Nov 2019 * ‌Source: Korea Health Industry Development Institute (KHIDI) (The * mark for the trade name indicates biosimilars, and ** mark for the trade name indicates generic medicine.) ‌• ‌Large-scale license agreements with global pharmaceutical companies are accelerating exports of technologies developed by Korean pharmaceutical companies.
Recommended publications
  • Annual Report and Financial Statements

    Annual Report and Financial Statements

    Annual Report and Financial Statements for the year ended 31 December 2018 Dimensional Funds ICVC Authorised by the Financial Conduct Authority No marketing notification has been submitted in Germany for the following Funds of Dimensional Funds ICVC: Global Short-Dated Bond Fund International Core Equity Fund International Value Fund United Kingdom Core Equity Fund United Kingdom Small Companies Fund United Kingdom Value Fund Accordingly, these Funds must not be publicly marketed in Germany. Table of Contents Dimensional Funds ICVC General Information* 2 Investment Objectives and Policies* 3 Authorised Corporate Directors’ Investment Report* 6 Incorporation and Share Capital* 10 The Funds 10 Fund Cross-Holdings 10 Authorised Status* 10 Regulatory Disclosure* 10 Potential Implications of Brexit* 10 Responsibilities of the Authorised Corporate Director 11 Responsibilities of the Depositary 11 Report of the Depositary to the Shareholders 11 Directors' Statement 11 Independent Auditors’ Report to the Shareholders of Dimensional Funds ICVC 12 The Annual Report and Financial Statements for each of the below sub-funds (the “Funds”); Emerging Markets Core Equity Fund Global Short-Dated Bond Fund International Core Equity Fund International Value Fund United Kingdom Core Equity Fund United Kingdom Small Companies Fund United Kingdom Value Fund are set out in the following order: Fund Information 14 Portfolio Statement* 31 Statement of Total Return 149 Statement of Change in Net Assets Attributable to Shareholders 149 Balance Sheet 150 Notes to the Financial Statements 151 Distribution Tables 168 Remuneration Disclosures (unaudited)* 177 Supplemental Information (unaudited) 178 * These collectively comprise the Authorised Corporate Directors’ (“ACD”) Report. Dimensional Fund Advisors Ltd. Annual Report and Financial Statements, 31 December 2018 1 Dimensional Funds ICVC General Information Authorised Corporate Director (the “ACD”): Dimensional Fund Advisors Ltd.
  • FTSE Korea 30/18 Capped

    FTSE Korea 30/18 Capped

    2 FTSE Russell Publications 19 August 2021 FTSE Korea 30/18 Capped Indicative Index Weight Data as at Closing on 30 June 2021 Index weight Index weight Index weight Constituent Country Constituent Country Constituent Country (%) (%) (%) Alteogen 0.19 KOREA Hyundai Engineering & Construction 0.35 KOREA NH Investment & Securities 0.14 KOREA AmoreG 0.15 KOREA Hyundai Glovis 0.32 KOREA NHN 0.07 KOREA Amorepacific Corp 0.65 KOREA Hyundai Heavy Industries 0.29 KOREA Nong Shim 0.08 KOREA Amorepacific Pfd. 0.08 KOREA Hyundai Marine & Fire Insurance 0.13 KOREA OCI 0.17 KOREA BGF Retail 0.09 KOREA Hyundai Merchant Marine 1.02 KOREA Orion 0.21 KOREA BNK Financial Group 0.18 KOREA Hyundai Mipo Dockyard 0.15 KOREA Ottogi 0.06 KOREA Celltrion Healthcare 0.68 KOREA Hyundai Mobis 1.53 KOREA Paradise 0.07 KOREA Celltrion Inc 2.29 KOREA Hyundai Motor 2.74 KOREA Posco 1.85 KOREA Celltrion Pharm 0.24 KOREA Hyundai Motor 2nd Pfd. 0.33 KOREA Posco Chemical 0.32 KOREA Cheil Worldwide 0.14 KOREA Hyundai Motor Pfd. 0.21 KOREA Posco International 0.09 KOREA CJ Cheiljedang 0.3 KOREA Hyundai Steel 0.33 KOREA S1 Corporation 0.13 KOREA CJ CheilJedang Pfd. 0.02 KOREA Hyundai Wia 0.13 KOREA Samsung Biologics 0.92 KOREA CJ Corp 0.11 KOREA Industrial Bank of Korea 0.22 KOREA Samsung C&T 0.94 KOREA CJ ENM 0.15 KOREA Kakao 3.65 KOREA Samsung Card 0.08 KOREA CJ Logistics 0.12 KOREA Kangwon Land 0.23 KOREA Samsung Electro-Mechanics 0.81 KOREA Coway 0.36 KOREA KB Financial Group 1.78 KOREA Samsung Electronics 25.36 KOREA Daewoo Engineering & Construction 0.12 KOREA KCC Corp 0.12 KOREA Samsung Electronics Pfd.
  • FTSE World Asia Pacific

    FTSE World Asia Pacific

    2 FTSE Russell Publications 19 August 2021 FTSE World Asia Pacific Indicative Index Weight Data as at Closing on 30 June 2021 Index weight Index weight Index weight Constituent Country Constituent Country Constituent Country (%) (%) (%) a2 Milk 0.04 NEW Asustek Computer Inc 0.1 TAIWAN Cheil Worldwide 0.02 KOREA ZEALAND ASX 0.12 AUSTRALIA Cheng Shin Rubber Industry 0.03 TAIWAN AAC Technologies Holdings 0.05 HONG KONG Atlas Arteria 0.05 AUSTRALIA Chiba Bank 0.04 JAPAN ABC-Mart 0.02 JAPAN AU Optronics 0.08 TAIWAN Chicony Electronics 0.02 TAIWAN Accton Technology 0.07 TAIWAN Auckland International Airport 0.06 NEW China Airlines 0.02 TAIWAN Acer 0.03 TAIWAN ZEALAND China Development Financial Holdings 0.07 TAIWAN Acom 0.02 JAPAN Aurizon Holdings 0.05 AUSTRALIA China Life Insurance 0.02 TAIWAN Activia Properties 0.03 JAPAN Ausnet Services 0.03 AUSTRALIA China Motor 0.01 TAIWAN ADBRI 0.01 AUSTRALIA Australia & New Zealand Banking Group 0.64 AUSTRALIA China Steel 0.19 TAIWAN Advance Residence Investment 0.05 JAPAN Axiata Group Bhd 0.04 MALAYSIA China Travel International Investment <0.005 HONG KONG ADVANCED INFO SERVICE 0.06 THAILAND Azbil Corp. 0.06 JAPAN Hong Kong Advantech 0.05 TAIWAN B.Grimm Power 0.01 THAILAND Chow Tai Fook Jewellery Group 0.04 HONG KONG Advantest Corp 0.19 JAPAN Bandai Namco Holdings 0.14 JAPAN Chubu Elec Power 0.09 JAPAN Aeon 0.2 JAPAN Bangkok Bank (F) 0.02 THAILAND Chugai Seiyaku 0.27 JAPAN AEON Financial Service 0.01 JAPAN Bangkok Bank PCL (NVDR) 0.01 THAILAND Chugoku Bank 0.01 JAPAN Aeon Mall 0.02 JAPAN Bangkok Dusit Medical Services PCL 0.07 THAILAND Chugoku Electric Power 0.03 JAPAN Afterpay Touch Group 0.21 AUSTRALIA Bangkok Expressway and Metro 0.02 THAILAND Chunghwa Telecom 0.17 TAIWAN AGC 0.08 JAPAN Bangkok Life Assurance PCL 0.01 THAILAND CIMB Group Holdings 0.08 MALAYSIA AGL Energy 0.04 AUSTRALIA Bank of East Asia 0.03 HONG KONG CIMIC Group 0.01 AUSTRALIA AIA Group Ltd.
  • Votebyvote Disclosure

    Votebyvote Disclosure

    ID on ISIN Item Date Type Ballot Name Count Voting Voting Voting Voting Action Agenda Agenda Vote By Vote By Country Meeting Meeting Meeting Numbers Investme Explanati Company Company nt Region Exception 1496011 HK0000065869 Guotai Junan International Holdings Limited Asia Hong Kong 20/01/2021 Special All For 1 1498193 HK0992009065 Lenovo Group Limited Asia Hong Kong 04/02/2021 Special All For 1 1502595 HK1208013172 MMG Ltd. Asia Hong Kong 04/03/2021 Special Against 1 Apparent failure to link pay and appropriate performance 1 1497186 JP3291200008 Kobe Bussan Co., Ltd. Asia Japan 28/01/2021 Annual All For 1 1497172 JP3780100008 Park24 Co., Ltd. Asia Japan 28/01/2021 Annual Against 1.6,1.7 Concerns about overall board structure 2 1499755 JP3229500008 Kansai Mirai Financial Group, Inc. Asia Japan 19/02/2021 Special All For 1 1499367 JP3170800001 OSG Corp. (6136) Asia Japan 20/02/2021 Annual Against 2.1 Concerns related to approach to board diversity 1 1501078 JP3244800003 Kewpie Corp. Asia Japan 25/02/2021 Annual All For 1 1501619 JP3786600001 Hitachi Capital Corp. Asia Japan 26/02/2021 Special Against 1 Concerns to protect shareholder value 1 1501608 JP3499800005 Mitsubishi UFJ Lease & Finance Co., Ltd. Asia Japan 26/02/2021 Special All For 1 1502471 JP3027670003 Nippon Building Fund, Inc. Asia Japan 09/03/2021 Special All For 1 1507489 JP3592200004 Toshiba Corp. Asia Japan 18/03/2021 Special Against 1 SH: For shareholder resolution, against management recommendation / Shareholder proposal promotes 1 transparency 1504139 JP3635500006 Trusco Nakayama Corp. Asia Japan 18/03/2021 Annual Against 1.7,3 Concerns about overall board structure 1 1506815 JP3266400005 Kubota Corp.
  • Voting Disclosure

    Voting Disclosure

    Notices: LGPS Central Limited is committed to disclosing its voting record on a vote-by-vote basis, including where practicable the provision of a rationale for votes cast against management. The data presented here relate to voting decisions for securities held in portfolios held within the company’s Authorised Contractual Scheme (ACS). Meeting Company Name Meeting Type Voting Action Agenda Item Numbers Voting Explanation 20/01/2021 Guotai Junan International Holdings Limited Special All For 04/02/2021 Lenovo Group Limited Special All For 04/03/2021 MMG Ltd. Special Against 1 Apparent failure to link pay and appropriate performance 05/03/2021 CSPC Pharmaceutical Group Ltd. Special Against 11.1 Concerns related to board gender diversity 12 Concerns related to shareholder rights 29/03/2021 China Resources Beer (Holdings) Co. Ltd. Special Against 2 Concerns related to board gender diversity 28/01/2021 Kobe Bussan Co., Ltd. Annual All For 28/01/2021 Park24 Co., Ltd. Annual Against 1.6,1.7 Concerns about overall board structure 19/02/2021 Kansai Mirai Financial Group, Inc. Special All For 20/02/2021 OSG Corp. (6136) Annual Against 2.1 Concerns related to approach to board diversity 25/02/2021 Kewpie Corp. Annual All For 26/02/2021 Hitachi Capital Corp. Special Against 1 Concerns to protect shareholder value 26/02/2021 Mitsubishi HC Capital, Inc. Special All For 09/03/2021 Nippon Building Fund, Inc. Special All For 18/03/2021 Toshiba Corp. Special Against 1 SH: For shareholder resolution, against management recommendation / Shareholder proposal promotes transparency 19/03/2021 Kubota Corp.
  • Employment of Veterinarians

    Employment of Veterinarians

    CONTENTS TOPIC PAGE Foreword 1 Summary of Project Since 1965 5 Veterinary Medicine in Kenya The Livestock Industry 8 Employment of Veterinarians 11 Livestock Diseases 14 Zoonoses 16 Research, Extension and Continuing Education 17 Operational Plan, Contract AID/afr-790 21 Scope of Work 22 Contract Staff 22 History of the Faculty of Veterinary Medicine 24 Beginning of Colorado State University Program of Technical Assistance 27 Faculty of Veterinary Medicine Structure 29 Undergraduate Program of Study 29 Structure of Curriculum 30 Courses of Study 30 Examination Sche2me 31 Outlines of Courses 33 Postgraduate Programs of Study 39 Faculty of Veterinary Medicine, Departmental Structure Clinical Studies 41 Pathology and Microbiology 43 Anatomy and Histology 45 Animal Physiology 46 Public Health, Pharmacology and Toxicology 47 Kenyanization of the Faculty 48 Government of Kenya Contribution to the Project 49 Professional Staff Supplied by C.S.U. Field Staff in Nairobi 54 Campus Coordinators 60 Administrative Staff 60 Recruitment of Field Staff 62 Publications by C.S.U. Field Staff 64 Publications by Counterparts 66 Unpublished Research 68 Post Graduate Courses 69 Graduate Student Supervision 70 International Meetings 72 External Examiners from C.S.U. 73 Participant and Counterpart Training Summary 74 Distribution of Participants in U.S. Universities 74 Selection of Participants 75 Support of Participants Upon Return-to Kenya 77 Participants 78 Counterpart Training 85 Final Reports of Field Staff Parasitology, Dr. A. E. Sollod 87 Clinical Studies,
  • FTSE Developed Asia Pacific All Cap

    FTSE Developed Asia Pacific All Cap

    FTSE Russell Publications 19 August 2018 FTSE Developed Asia Pacific All Cap Indicative Index Weight Data as at Closing on 29 June 2018 Index weight Index weight Index weight Constituent Country Constituent Country Constituent Country (%) (%) (%) 77 Bank 0.02 JAPAN Anritsu 0.03 JAPAN Azbil Corp. 0.04 JAPAN a2 Milk 0.08 NEW Ansell 0.04 AUSTRALIA Bandai Namco Holdings 0.11 JAPAN ZEALAND Anton Oilfield Services <0.005 HONG KONG Bando Chem Inds 0.01 JAPAN AAC Technologies Holdings 0.14 HONG KONG AOI Electronics <0.005 JAPAN Bank of East Asia 0.07 HONG KONG Abacus Property Group 0.01 AUSTRALIA Aoki Holdings 0.01 JAPAN Bank of Iwate 0.01 JAPAN ABC-Mart 0.02 JAPAN Aomori Bank 0.01 JAPAN Bank of Kyoto 0.05 JAPAN Able C&C <0.005 KOREA Aoyama Trading 0.02 JAPAN Bank of Nagoya 0.01 JAPAN Accent Group 0.01 AUSTRALIA Aozora Bank 0.06 JAPAN Bank of Okinawa 0.01 JAPAN Accordia Golf Trust <0.005 SINGAPORE APA Group 0.12 AUSTRALIA Bank of Queensland Ltd. 0.04 AUSTRALIA Achilles <0.005 JAPAN Aplus Financial <0.005 JAPAN Bank of Ryukyus 0.01 JAPAN Acom 0.02 JAPAN APN Outdoor Group 0.01 AUSTRALIA Bank of Saga <0.005 JAPAN Adastria Holdings <0.005 JAPAN Appen 0.01 AUSTRALIA Bapcor 0.02 AUSTRALIA Adeka 0.02 JAPAN Aprogen Pharmaceuticals <0.005 KOREA Beach Energy 0.03 AUSTRALIA Adelaide Brighton 0.03 AUSTRALIA Arakawa Chemical Industries <0.005 JAPAN Beadell Resources <0.005 AUSTRALIA Advan <0.005 JAPAN Arata 0.01 JAPAN Bega Cheese 0.01 AUSTRALIA Advanced Process Systems <0.005 KOREA ARB Corporation 0.02 AUSTRALIA Beijing Enterprises Medical and Health <0.005
  • FTSE Developed Asia Pacific All Cap

    FTSE Developed Asia Pacific All Cap

    FTSE PUBLICATIONS 19 November 2016 FTSE Developed Asia Pacific All Cap Indicative Index Weight Data as at Closing on 30 September 2016 Index weight Index weight Index weight Constituent Country Constituent Country Constituent Country (%) (%) (%) 13 Holdings <0.005 HONG KONG Anest Iwata 0.01 JAPAN AWE <0.005 AUSTRALIA 360 Capital Industrial Fund 0.01 AUSTRALIA Anicom Holdings 0.01 JAPAN Axial Retailing 0.01 JAPAN 3S Korea <0.005 KOREA Anritsu 0.01 JAPAN Azbil Corp. 0.04 JAPAN 77 Bank 0.02 JAPAN Ansell 0.04 AUSTRALIA Bandai Namco Holdings 0.1 JAPAN a2 Milk 0.02 NEW Anton Oilfield Services <0.005 HONG KONG Bando Chem Inds 0.01 JAPAN ZEALAND AOI Electronics <0.005 JAPAN Bank of East Asia 0.08 HONG KONG AAC Technologies Holdings 0.12 HONG KONG Aoki Holdings 0.01 JAPAN Bank of Iwate 0.01 JAPAN Abacus Property Group 0.01 AUSTRALIA Aomori Bank 0.01 JAPAN Bank of Kyoto 0.04 JAPAN ABC-Mart 0.03 JAPAN Aoyama Trading 0.03 JAPAN Bank of Nagoya 0.01 JAPAN Able C&C <0.005 KOREA Aozora Bank 0.07 JAPAN Bank of Okinawa 0.01 JAPAN Accordia Golf 0.01 JAPAN APA Group 0.12 AUSTRALIA Bank of Queensland Ltd. 0.05 AUSTRALIA Accordia Golf Trust 0.01 SINGAPORE Aplus Financial <0.005 JAPAN Bank of Ryukyus 0.01 JAPAN Achilles <0.005 JAPAN APN News & Media 0.01 AUSTRALIA Bank of Saga 0.01 JAPAN Acom 0.03 JAPAN APN Outdoor Group 0.01 AUSTRALIA Bapcor 0.02 AUSTRALIA Aconex 0.01 AUSTRALIA Apt Satellite <0.005 HONG KONG Beach Energy 0.01 AUSTRALIA Acrux <0.005 AUSTRALIA ARA Asset Management 0.01 SINGAPORE Beadell Resources 0.01 AUSTRALIA Adastria Holdings 0.01 JAPAN Arakawa
  • FTSE Asia Pacific Ex Japan, Australia and NZ

    FTSE Asia Pacific Ex Japan, Australia and NZ

    FTSE PUBLICATIONS FTSE Asia Pacific ex Japan, 19 February 2017 Australia and NZ Indicative Index Weight Data as at Closing on 30 December 2016 Index Index Index Constituent Country Constituent Country Constituent Country weight (%) weight (%) weight (%) 3SBio (P Chip) 0.03 CHINA Bank Negara Indonesia 0.09 INDONESIA Champion REIT 0.04 HONG AAC Technologies Holdings 0.19 HONG Bank of Baroda 0.03 INDIA KONG KONG Bank of China (H) 1.01 CHINA Chang Hwa Commercial Bank 0.09 TAIWAN ABB India 0.02 INDIA Bank of Communications (H) 0.18 CHINA Charoen Pokphand Foods PCL 0.11 THAILAND Aboitiz Equity Ventures 0.1 PHILIPPINES Bank of East Asia 0.14 HONG Charoen Pokphand Indonesia Tbk 0.05 INDONESIA Aboitiz Power 0.04 PHILIPPINES KONG Cheil Worldwide 0.03 KOREA ACC 0.03 INDIA Bank of India 0.01 INDIA Cheng Shin Rubber Industry 0.11 TAIWAN Acer 0.04 TAIWAN Bank of The Philippine Islands 0.09 PHILIPPINES Cheng Uei Precision Industry 0.01 TAIWAN Adani Enterprises 0.01 INDIA Bank Rakyat Indonesia 0.28 INDONESIA Cheung Kong Infrastructure Holdings 0.15 HONG Adani Ports and Special Economic Zone 0.1 INDIA Banpu 0.07 THAILAND KONG Adani Power 0.01 INDIA BBMG (H) 0.02 CHINA Cheung Kong Property Holdings 0.52 HONG Adaro Energy PT 0.05 INDONESIA BDO Unibank 0.1 PHILIPPINES KONG Aditya Birla Nuvo 0.02 INDIA BEC World 0.01 THAILAND Chicony Electronics 0.04 TAIWAN Advanced Info Serv 0.15 THAILAND Beijing Capital International Airport (H) 0.05 CHINA China Agri-Industries Holdings (Red Chip) 0.02 CHINA Advanced Semiconductor Engineering 0.19 TAIWAN Beijing Enterprises Holdings (Red Chip) 0.07 CHINA China Airlines 0.02 TAIWAN Advantech 0.08 TAIWAN Beijing Enterprises Water Group (Red Chip) 0.08 CHINA China BlueChemical (H) 0.02 CHINA Agile Group Holdings (P Chip) 0.02 CHINA Beijing Jingneng Clean Energy (H) 0.02 CHINA China Cinda Asset Management (H) 0.1 CHINA Agricultural Bank of China (H) 0.32 CHINA Beijing North Star (H) 0.01 CHINA China Citic Bank (H) 0.16 CHINA AIA Group Ltd.
  • In Brief... Biotech and Pharma M&A in South Korea Heats up Shanghai Pharmaceutical Co., Ltd. Joins IFPW

    In Brief... Biotech and Pharma M&A in South Korea Heats up Shanghai Pharmaceutical Co., Ltd. Joins IFPW

    Vol. 26, Vol. 13 FOCUS International Federation of Pharmaceutical Wholesalers July 11, 2019 In Brief... Walgreens Boots Alliance announced its third quarter 2019 earnings, with sales of US$34.6 billion, an increase of Shanghai Pharmaceutical Co., Ltd. 0.7% attributed to growth in its American retail pharmacy and pharmaceutical wholesale divisions. Net earnings came Joins IFPW in at US$1 billion (a 23.6% decrease over the same quarter (Source: IFPW press Release) in the prior year.) “Following a difficult second quarter, we Shanghai Pharmaceutical Co., Ltd. (hereinafter referred made progress in the third quarter against the strategic goals to as “SHAPHAR”) is a wholly-owned subsidiary of Shanghai we set, and are pleased to report an improvement in our Pharmaceuticals Holding Co., Ltd., and the first domestic pharmaceutical company listed both in Shanghai and Hong Kong. It U.S. comparable growth compared to the first half of the is a national modern pharmaceutical supply chain service company year,” said WBA executive vice chairman and CEO, Stefano covering the whole pharmaceutical value chain including medicine, Pessina. Internationally, WBA saw retails pharmacy sales medical devices, I and cosmetic surgery products. The company of US$2.8 billion, a 7.3% decrease over the prior year, and a has long ranked as the top three in the Chinese pharmaceutical reflection of a 5.7% adverse currency impact. The company’s distribution industry. In 2018, it achieved sales revenues of nearly pharmaceutical wholesale division realized sales of US$5.9 RMB 140 billion (US$20.4 billion), and has had a nearly15% billion.
  • WHO Monographs on Selected Medicinal Plants. Volume 3

    WHO Monographs on Selected Medicinal Plants. Volume 3

    WHO monographs on WHO monographs WHO monographs on WHO published Volume 1 of the WHO monographs on selected medicinal plants, containing 28 monographs, in 1999, and Volume 2 including 30 monographs in 2002. This third volume contains selected an additional collection of 32 monographs describing the quality control and use of selected medicinal plants. medicinal Each monograph contains two parts, the first of which provides plants selected medicinal plants pharmacopoeial summaries for quality assurance purposes, including botanical features, identity tests, purity requirements, Volume 3 chemical assays and major chemical constituents. The second part, drawing on an extensive review of scientific research, describes the clinical applications of the plant material, with detailed pharmacological information and sections on contraindications, warnings, precautions, adverse reactions and dosage. Also included are two cumulative indexes to the three volumes. The WHO monographs on selected medicinal plants aim to provide scientific information on the safety, efficacy, and quality control of widely used medicinal plants; provide models to assist Member States in developing their own monographs or formularies for these and other herbal medicines; and facilitate information exchange among Member States. WHO monographs, however, are Volume 3 Volume not pharmacopoeial monographs, rather they are comprehensive scientific references for drug regulatory authorities, physicians, traditional health practitioners, pharmacists, manufacturers, research scientists
  • Korea Innovative PHARMACEUTICAL Company Potential of Pharmaceutical Industry in Korea

    Korea Innovative PHARMACEUTICAL Company Potential of Pharmaceutical Industry in Korea

    2018 Korea Innovative PHARMACEUTICAL Company Potential of Pharmaceutical Industry in Korea Aging populations and growing interest in health and welfare continue to drive up the demand for innovative drugs across the world. Globally, R&D spending in the pharmaceutical industry was higher than any other industry (pharmaceutical and bio ranked No. 1 with 150 billion dollars(2015)), indicating that the future industrial structure is shifting from IT to pharmaceutical business. Pharmaceutical Industry in Korea In Korean, the value of drugs manufactured in Korea was KRW 18.8 trillion in 2016. The annual average growth rate for the past five years was 4.6 percent. In addition, the size of the pharmaceutical market was KRW 21.7 trillion in 2016. Size and Market Trends in Pharmaceutical Industry in Korea (Unit: KRW Trillion) Category Production Export Import Balance Market size 2012 157,140 23,409 58,535 △35,126 192,266 2013 163,761 23,306 52,789 △29,483 193,244 2014 164,194 25,442 54,952 △29,510 193,704 2015 169,696 33,348 56,016 △22,668 192,364 2016 188,061 36,209 65,404 △29,195 217,256 YOY 10.8% 8.6% 16.8% - 12.9% CAGR(’12~’16) 4.6% 11.5% 2.8% - 3.1% Note: 1) Pharmaceutical products include finished products, narcotic drugs, ultra narcotic, psychotropic substance and drug substance 2) Numbers in export and import categories are calculated in Korean won and converted US dollar by using annual average exchange rate at Bank of Korea 3) Market Size= Production-Export+Import Source: Pharmaceutical Industry Statistics, Korea Pharmaceutical and Bio-Pharma Manufacturers Association Facts & Survey Report, Korea Pharmaceutical Traders Association, Korea Health Industry Statistics System Based on its technological competitiveness and quality drugs, the pharmaceutical industry in Korea has taken a stride in strengthening its ability to develop innovative drugs in a short period of time, including R&D, clinical trials and drug manufacturing.